Abstract:BACKGROUND AND OBJECTIVE:Gemcitabine is used as an effective drug for patients with advanced pancreatic cancer. Serum CA19-9 has been proven as the most sensitive and specific serum marker for pancreatic cancer. This study was to investigate the value of serum CA19-9 in evaluating treatment efficacy and predicting prognosis of patients with pancreatic cancer treated by gemcitabine-based chemotherapy. METHODS:Seventy-one patients with histologically confirmed, locally advanced or metastatic pancreatic adenocarcinoma, whose karnofsky's performance status (KPS) score was >or= 70 were treated with gemcitabine alone or with gemcitabine-based chemotherapy. CA19-9 was measured before and after chemotherapy. RESULTS:Ten out of 71 patients had normal baseline CA19-9 levels, and 61 patients had increased baseline CA19-9 levels. The overall survival of patients were similar between the two groups, which were 9.0 months and 7.9 months respectively (P=0.797). The median baseline CA19-9 level for patients who had increased CA19-9 was (682+/-558) U/mL before treatment. Patients whose pretreatment CA19-9 levels were <682 U/mL achieved better survival than those whose pretreatment CA19-9 levels were >or=682 U/mL (9.6 months vs. 5.1 months, p=0.001). In addition, patients with a pretreatment CA19-9 level of <682 U/mL also had a better tumor response (43.5% vs. 15.8%, p=0.051) and clinical benefit response (48.1% vs. 29.2%, P=0.125) than those whose pretreatment CA19-9 level was <682 U/mL, but the differences were not significant. Patients with a fall of >or=25% in the baseline CA19-9 level after chemotherapy achieved a longer median overall survival (10.2 months vs. 5.0 months, p<0.001), better tumor response (47.8% vs. 10.5%, p=0.002) and better clinical benefit response (69.2% vs. 8.0%, P=0.000) than those without a decrease of baseline CA19-9 or with a fall of <25%. Multivariate analysis revealed that the baseline CA19-9 level before chemotherapy, decreased percentage of the CA19-9 level after chemotherapy, and the differentiation degree of tumor cells were independent risk factors for patients whose baseline CA19-9 levels were increased. CONCLUSION:The level of pretreatment base-line CA19-9 and the decreased percentage of baseline CA19-9 level after chemotherapy are of predictive values for survival of patients with advanced pancreatic cancer undergoing gemcitabine-based chemotherapy and with an increased level of baseline CA19-9.

Prognostic Role of Human Equilibrative Nucleoside Transporter 1 in Patients with Pancreatic Cancer Receiving Gemcitabine Treatment: A Meta Analysis

Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.

Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer

Relation of HENT1 Mrna Expression with the Prognosis of Non-Small Cell Lung Cancer Patients Received Gemcitabine-Based Chemotherapy

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

"Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer

Hent1’s Role in Adjuvant Intra-Arterial Gemcitabine-Based Chemotherapy for Resectable Pancreatic Cancer Patients

Gemcitabine Sensitivity Factors, Hent1 and RRM1 As Potential Prognostic Biomarker for Advanced Biliary Tract Cancer.

Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.

Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma

The Clinicopathological and Prognostic Implications of Tyrosine Phosphatase SHP2 and Ankyrin Hook1 Gene Expression in Non- Small Cell Lung Cancer Patients Treated with Gemcitabine Plus Platinum As First-Line Chemotherapy

The prognostic value of chemotherapy -induced neutropenia in metastatic pancreatic cancer patients undergoing first-line chemotherapy with GS

Hent1 Reverses Chemoresistance by Regulating Glycolysis in Pancreatic Cancer

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer

[Prognostic Value of Serum CA19-9 in Patients with Advanced Pancreatic Cancer Receiving Gemcitabine Based Chemotherapy].

Clinical Significance of H-Tert and C-Met Expression in the Peripheral Blood Circulation of Pancreatic Cancer Patients

Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy

Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression Level Is a Potential Predictive Tool For Response To Decitabine In Patients With Myelodysplastic Syndrome